Knowlexaconnect Knowlexaconnect
Rezultatele cautarii
Vedeti tot
  • Conecteaza-te
    Conecteaza-te
    Inscrie-te
    Căutare
    Night Mode

Căutare

Descoperă oameni noi, creează noi conexiuni și faceti-va noi prieteni

  • News Feed
  • EXPLORE
  • Pagini
  • Grupuri
  • Events
  • Reels
  • Blogs
  • Offers
  • Jobs
  • Postari
  • Blogs
  • Utilizatori
  • Pagini
  • Grupuri
  • Events
  • Vandana Manturgekar a adăugat un sunet Home
    2026-01-09 07:22:44 -
    Biomarkers For Signing Cancer Market Revenue, Trends, Analysis, Demand and Forecast to 2032
    The Biomarkers For Signing Cancer Market was valued at USD 5.2 billion in 2024 and is projected to reach USD 12.8 billion by 2034, registering a CAGR of 9.2%. This growth trajectory is underpinned by several factors, including the increasing prevalence of cancer globally, advancements in biomarker research, and the rising demand for personalized medicine. The growing emphasis on early detection...
    0 Commentarii 0 Distribuiri 221 Views 0 previzualizare
    Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
  • Isha Deshpande a adăugat un sunet Alte
    2026-01-09 07:33:59 -
    Executive Brief: Competitive Landscape and Strategic Developments in the Advanced Pancreatic Cancer Market
    The Advanced Pancreatic Cancer Market was valued at USD 3.5 billion in 2024 and is projected to reach USD 7.2 billion by 2034, registering a CAGR of 7.5%. This growth trajectory is underpinned by several key factors, including the rising incidence of pancreatic cancer, advancements in treatment modalities, and increasing awareness regarding early diagnosis and treatment options. The global...
    0 Commentarii 0 Distribuiri 109 Views 0 previzualizare
    Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
  • Deng Yue a adăugat un sunet Health
    2026-01-30 09:21:22 -
    Targeting the Cell Cycle to Safeguard Hope: The Clinical Value and Development of CDK4/6 Inhibitors
    Written by DengyuePharma As cancer treatment enters the era of precision medicine, the emergence of each novel targeted therapy has brought renewed hope to countless patients. CDK4/6 inhibitors, a class of targeted agents focusing on cell cycle regulation, have established a central role in the treatment of hormone receptor–positive (HR+), human epidermal growth factor receptor...
    0 Commentarii 0 Distribuiri 79 Views 0 previzualizare
    Vă rugăm să vă autentificați pentru a vă dori, partaja și comenta!
© 2026 Knowlexaconnect Romaian
English Arabic French Spanish Portuguese Deutsch Turkish Dutch Italiano Russian Romaian Portuguese (Brazil) Greek
Contacteaza-ne Director